Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Johnson & Johnson (JNJ) is cut to Sell with $72 price target at Goldman, which projects just...

  • Tuesday, October 9, 2012, 7:47 AM ET
    Johnson & Johnson (JNJ) is cut to Sell with $72 price target at Goldman, which projects just 7% upside for the stock vs. double that for the rest of the pharmaceutical group (see Eli Lilly upgrade). "We see JNJ as lacking transformational pipeline opportunities." Shares -1.2% premarket.
Track new comments on this story

This news story has 1 comment:

  •  
    This is literally right next to the comment concerning LLY where their "skepticism was proven wrong" Pardon me if I don't a $%*#$ about what Goldman thinks about JNJ LOL
    9 Oct 2012, 08:12 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »